Genetic contributions to the development of complications in preterm newborns by Poggi, Chiara et al.
RESEARCH ARTICLE
Genetic Contributions to the Development of
Complications in Preterm Newborns
Chiara Poggi1, Betti Giusti2, Elena Gozzini1, Alice Sereni2, Ilaria Romagnuolo2,3,
Ada Kura2, Elisabetta Pasquini4, Rosanna Abbate2, Carlo Dani5*
1 Division of Neonatology, Careggi University Hospital of Florence, Florence, Italy, 2 Department of
Experimental and Clinical Medicine, University of Florence - Atherothrombotic Diseases Centre, Careggi
University Hospital of Florence, Florence, Italy, 3 Department of Information Engineering University of
Florence, Florence, Italy, 4 Metabolic and Muscular Unit, Clinic of Pediatric Neurology, Meyer Children's
Hospital, Florence, Italy, 5 Department of Neurosciences, Psychology, Drug Research and Child Health,
Careggi University Hospital of Florence, Florence, Italy
* cdani@unifi.It
Abstract
Aim
We aimed to identify specific polymorphisms of genes encoding for vascular endothelial
growth factor A (VEGFA), endothelial nitric oxide synthase (eNOS), renin-angiotensin sys-
tem (angiotensinogen gene [AGT], angiotensinogen type 1 receptor [AGTR1], angiotensin-
converting enzyme [ACE]), and heme oxygenase-1 (HMOX-1) in a cohort of preterm infants
and correlate their presence with the development of respiratory distress syndrome (RDS)
requiring mechanical ventilation (MV), bronchopulmonary dysplasia (BPD), intraventricular
hemorrhage (IVH) and retinopathy of prematurity (ROP).
Study Design
We carried out a retrospective study to evaluate the allele frequency and genotype distribu-
tion of polymorphisms of VEGFA, eNOS, AGT, AGTR1, ACE, and HMOX-1 in a population
of preterm neonates (n=342) with a gestational age28 weeks according to the presence
or absence of RDS requiring MV, BPD, IVH, or ROP. Moreover, we evaluated through the
haplotype reconstruction analysis whether combinations of the selected polymorphisms are
related to the occurrence of RDS, BPD, IVH and ROP.
Results
In our population 157 infants developed RDS requiring MV, 71 BPD, 70 IVH, and 43 ROP.
We found that TC+CC rs2070744 eNOS (41.7 vs. 25.4%, p=0.01) and GT+TT rs1799983
eNOS (51.8 vs. 35.2%, p=0.01) polymorphisms are independent risk factors for BPD. Hap-
lotype reconstruction showed that haplotypes in VEGF and eNOS are significantly associ-
ated with different effects on RDS, BPD, IVH, and ROP in our population.
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Conclusions
We found that TC+CC rs2070744 eNOS and GT+TT rs1799983 eNOS polymorphisms are
independent predictors of an increased risk of developing BPD. Haplotypes of VEGFA and
eNOSmay be independent protective or risk markers for prematurity complications.
Introduction
There is increasing evidence that some genepolymorphismsare implicated in the development
of severe complications of preterm birth, including respiratory distress syndrome (RDS),
bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), and retinopathy of
prematurity (ROP).
Vascular endothelial growth factor A (VEGFA) is important for the physiological growth of
retinal vessels, and experimental and clinical data suggest that VEGF may play a causative role
in the development of ROP [1]. Similarly, VEGFA plays a central role in vascular lung repair
and its absence results in impaired fetal lung microvascular development [2]. Accordingly, clin-
ical studies suggest a relevant association between VEGFA activity and BPD development in
preterm infants [3,4].
Nitric oxide (NO) has several vascular actions which may contribute to the growth and pro-
tection of vessels in preterm infants [5]. This seems to be confirmed by the reported association
between endothelial NO synthase (eNOS) gene activity and the risk of developing RDS, BPD,
and IVH in this population [6].
The renin-angiotensin system (RAS) is important for regulating systemic blood pressure
and volume, and its genetic modifications could affect the outcome of preterm infants. Previ-
ous studies have reported the possible association between angiotensin-converting enzyme
(ACE) and angiotensin type 1 receptor (AGTR1) polymorphisms and the risk of developing
BPD [7–10] and ROP [11–12], but results are still inconclusive.
Heme oxygenase-1 (HMOX-1) is an enzyme degrading heme to iron ions, carbon monox-
ide, and biliverdin. Products of HO-1 activity perform important physiological functions in the
vascular system, which are ultimately linked to the protection of endothelium through cytopro-
tective, promitogenic, and anti-inflammatory action [13]. The efficacy of this enzyme has been
found to be affected by repeat polymorphisms in the promoter of HMOX-1 gene [13].
Although ample clinical data indicate its influence on cardiovascular complications in adult
patients, the possible correlation between HMOX-1 gene transcription and the outcome in pre-
term infants has never been investigated.
On the basis of these considerations, we hypothesized that the occurrence of severe compli-
cations in preterm infants—RDS requiring mechanical ventilation (MV), BPD, IVH and ROP
—might be affected by polymorphisms in genes coding the VEGFA, eNOS enzyme, RAS system
(Angiotensinogen gene [AGT], AGTR1,ACE), and HMOX-1 enzyme. To assess this hypothesis
we aimed to genotype specific polymorphisms of these genes in a cohort of preterm infants
and correlate their presence to the development of RDS requiring MV, BPD, IVH, and ROP.
Materials and Methods
We performed this study following approval of the local medical ethics committee of Careggi
University Hospital. Parental consent was not obtained because patient records/information
were rendered anonymous and de-identified prior to analysis.
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Study design
We carried out a retrospective study to evaluate the possible relationship between twelve poly-
morphisms in genes encoding forVEGFA, eNOS, RAS system, andHMOX-1 and the occurrence
of RDS requiring MV, BPD, IVH and ROP in a population of preterm newborns. By using hap-
lotype reconstruction analysis we evaluated whether combinations of the selected polymor-
phisms are related to the occurrence of the aforementioned prematurity complications.
Patient population
We studied 342 preterm neonates with a gestational age28 weeks, admitted consecutively to
the Neonatal Intensive Care Unit of the Careggi University Hospital of Florence, from January
2004 to December 2012. Exclusion criteria were the diagnosis of major congenital malforma-
tions, inherited errors of metabolism, and any other congenital syndrome. All subjects investi-
gated were of Caucasian origin in order to guarantee a homogenous ethnic background.
The DNA analysis was performed on dried blood spots collected from infants at 48 hours of
life for the local screening program [14].
Clinical Features and Outcome
Birth weight, gestational age, type of delivery, antenatal steroid treatment, gender, Apgar Score
at 5 min, RDS occurrence, need of MV and surfactant, type and duration of respiratory assis-
tance [nasal continuous positive airways pressure (NCPAP), patient-triggered ventilation
(PTV),high frequency oscillatory ventilation (HFOV)] were recorded for each newborn infant.
The RDS diagnosis was made as previously reported [15]. Infants were given MV when the
pH was<7.20, pO2 was<50 mmHg with FiO2>0.50, and pCO2 was>65 mmHg.
We reported the occurrence of patent ductus arteriosus (PDA), sepsis, IVH, periventricular
leukomalacia (PVL),BPD, necrotizing enterocolitis (NEC), ROP, and mortality. Diagnosis of
BPD was based on the need for supplemental oxygen to maintain adequate oxygenation at36
weeks of post-conceptional age [16]. Intraventricular hemorrhage, PVL, and NEC were diag-
nosed following Papile’ [17], de Vries’ [18], and Bell’s criteria [19], respectively. ROP was diag-
nosed following the International Classification criteria [20].
All clinical data were reported on data sheets designed for this study.
Studied polymorphisms
The criteria for selection of candidate genes in the present study were their potential involve-
ment in the pathogenesis of the aforementioned prematurity complications. The DNA analysis
was performed on dried blood spots collected from infants at 48 hours of life for the local
screening program using the QIAamp DNAMicro Kit according to the manufacturer’s
instructions (QiagenGmbh, Hilden, Germany).
We studied 12 single nucleotide polymorphisms (SNPs) in the 6 candidate genes (ACE,
AGTR1, AGT, eNOS, VEGFA,HMOX-1) according to their demonstrated or putative function
based on literature data, localization in the functional regions, as extracted from the dbSNP
database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db = snp&cmd = search&term=)
(Table 1). SNP information was assessed in dbSNP NCBI and ENSEMBL (http://www.
ensembl.org/index.html) databases.
Genotyping of ACE gene Insertion/Deletion (I/D) polymorphisms was performed by Taq-
Man designed assay, according to Koch et al. [21]. The eNOS 4a4b polymorphism was evalu-
ated by PCR method, as previously described [22].
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The other polymorphisms [ACE rs4291; AGTMrs699; AGTR1 rs5186; eNOSrs2070744 and
rs1799983; VEGFA rs1547651,rs833058, rs833061 and rs3025039] were analyzed by using Taq-
Man SNP genotyping assays through the real-time PCR (7900HT Fast Real-Time PCR System,
Life Technologies Italia, Monza, Italy).
The (GT)n repeat polymorphism in the promoter of HMOX-1 was detected according to
Vazquez-Armenta G et al. [23].
Data analysis
Statistical analysis was performed using the SPSS package v18.0. Continuous variables were
expressed as mean and standard deviation, and categorical variables were expressed as frequen-
cies and percentages. Tests for conformity with Hardy—Weinberg equilibrium were performed
using a standard χ2 test. Genotype distributions were compared between groups by χ2 analysis.
We assessed the association between each polymorphism and clinical adverse outcomes (RDS,
BPD, IVH, ROP) by using a dominant model of inheritance, which compares individuals with
one or two rare alleles (heterozygotes+homozygotes) to a baseline group of homozygous wild
type subjects.
The association of the studied polymorphisms with gestational age and birth weight was
also evaluated. Comparisons between median values of gestational age and birth weight among
genotypes were performed using the non-parametric Mann-Whitney U test. Logistic regression
analysis was used to estimate odds ratios (OR) and 95% confidence intervals (CIs). The inde-
pendent association of polymorphisms with the different clinical endpoints was evaluated by
logistic regression analysis adjusted for gestational age and weight at birth. A value of p = 0.05
was chosen as the cut-off level for statistical significance.
Haplotype analysis
In order to perform haplotype reconstruction analysis (to infer the most probable set of poly-
morphisms of each studied gene that are inherited together from one parent) in our popula-
tion, data files were processed in R environment (http://www.r-project.org). Haplotype
Table 1. Description of the 12 studied single nucleotide polimorphisms (SNPs) in ACE, AGTR1, AGT, eNOS, VEGF andHMOX1 genes.
Gene Symbol Chr.
Position
Reference
Sequence Number
db SNP ID number(Taqman
assay number)
Common SNP name and
nucleotide substitution
Region Relative
Distance
ACE17q23.3 NG_011648.1 rs4291(C__11942507_10) -240A>T 5’ near gene
(promotor)
0
rs1799752 Custom TaqMan SNP
Genotyping Assays
Alu I/D (287 bp) Intron 16 11696
AGTR13q24 NG_008468.1 rs5186(C___3187716_10) 1166 A>C 3’-UTR 0
AGT1q42.2 NG_008836.1 rs699(C___1985481_20) 803 A>GMet 235 Thr Exon 2 0
eNOS NG_011992.1 rs2070744 (C__15903863_10) -786 T>C 5’ near gene 0
7q36
rs61722009 eNOS 4a4b Intron 4 4147
rs1799983(C___3219460_20) 894 G>TGlu298Asp Exon 7 5866
VEGFA NG_008732.1 rs1547651(C___8311590_10) A>T 5’ near gene 0
6p12
rs833058(C___1647396_20) C>T 5’ near gene 1210
rs833061(C___1647381_10) -460 T>C 5’ near gene 6842
rs3025039(C__16198794_10) 936C>T 3’-UTR 21892
HMOX122q13.1 rs3074372 GT repeat 5’ near gene 0
doi:10.1371/journal.pone.0131741.t001
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reconstruction and frequency estimation were independently performed using the PHASE v2.1
software [24], and R package haplo.stats by expectation-maximization strategy (EM algo-
rithm). The haplo.stats package was also used to identify statistically significant associations
between haplotypes and clinical endpoints by means of generalized linear models: positive or
negative coefficient values indicate the risk or the protection conferred by the haplotypes,
respectively, and the absolute values of the coefficient indicate the magnitude of the associa-
tions. In order to reduce the type I error, we applied the false discovery rate (FDR) multiple
testing correction in generalized linear model analysis [25].
Results
We found that 157 infants developed RDS requiring MV, 71 BPD, 70 IVH, and 43 ROP in our
study population (S1 Appendix). Table 2 shows clinical and demographic data of the enrolled
preterm infants. Genotype distributions and allele frequencies of twelve polymorphisms inves-
tigated in our population are shown in Table 3.
There was a higher prevalence of TC+CC rs2070744 eNOS (74.6 vs 58.3%, p = 0.01) and GT
+TT rs1799983 eNOS (64.8 vs 48.0%, p = 0.01) polymorphisms in infants with BPD compared
to those without BPD (Table 4). Multivariate analysis indicates that these associations were sta-
tistically significant [TC+CC rs2070744: OR 1.89 (1.03–3.46), p = 0.04; GT+TT rs1799983:
OR1.92 (1.09–3.39), p = 0.02] after adjustment for gestational age and birth weight (Table 5).
The contemporary presence of TC or CC rs2070744 and GT or TT rs1799983 eNOS genotypes
was associated with an increased OR for BPD (OR 2.26 (1.30–3.95), p = 0.004).
We observed a trend toward a different prevalence of AT+TT rs4291 ACE polymorphism of
the promoter region, MT+TT rs699 AGT, and CT+TT rs3025039 VEGFA polymorphisms in
infants with BPD compared to those without BPD (Table 4), and of GT+TT rs1799983 eNOS
in infants with ROP compared to those without ROP (Table 6). However, these associations
disappeared after adjusting for gestational age and birth weight (Table 5).
Table 2. Demographic and clinical characteristics of enrolled infants. Mean±SD and rate and (%).
Characteristics n = 342
Birth weight (g) 915 ± 249
Gestational age (wks) 27.1 ± 1.8
Cesarean delivery, n (%) 227 (67)
Antenatal steroids, n (%) 240 (71)
Male, n (%) 160 (47)
Apgar score at 5’th min 7.9 ± 0.86
RDS 160 (47)
Mechanical Ventilation 157 (46)
Surfactant 299 (87)
PDA 279 (82)
Sepsis 86 (25)
IVH 70 (21)
PVL 12 (4)
BPD 71 (21)
NEC 9 (3)
ROP 43 (13)
Death 23 (15)
doi:10.1371/journal.pone.0131741.t002
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Table 3. Genotype distribution and allele frequency of the studied polymorphisms.
Gene Symbol dbSNP Genotypes n (%) F MAF
ACE rs1799752 II 58 (16.9)
ID 166 (48.5)
DD 118 (34.6)
D 0.59 0.51°
ACE Prom rs4291 AA 119 (34.8)
AT 171 (50.0)
TT 52 (15.2)
T 0.40 0.39°
AGTR1 rs5186 AA 211 (61.7)
AC 108 (31.9)
CC 22 (6.4)
C 0.22 0.29°
AGT rs699 MM 85 (24.9)
MT 166 (49.1)
TT 89 (26.0)
T 0.51 0.43°
eNOS rs2070744 TT 131 (38.3)
TC 147 (43.0)
CC 64 (18.7)
C 0.40 0.41°
rs1799983 GG 166 (48.5)
GT 145 (42.4)
TT 31 (9.1)
T 0.30 0.36°
rs61722009 bb 247 (72.2)
ab 85 (24.9)
aa 10 (2.9)
a 0.15 0.17°
VEGFA rs3025039 CC 240 (70.2)
CT 88 (25.7)
TT 14 (4.1)
T 0.17 0.15*
rs1547651 AA 255 (74.6)
AT 77 (22.5)
TT 10 (2.9)
T 0.14 0.13*
rs833058 CC 109 (31.9)
CT 160 (46.8)
TT 73 (21.3)
T 0.45 0.39*
rs833061 TT 99 (28.9)
TC 170 (49.7)
CC 73 (21.3)
C 0.46 0.38*
HMOX1 rs3074372 LL 150 (43.8)
SL 162 (47.4)
SS 30 (8.8)
S 0.31 -
doi:10.1371/journal.pone.0131741.t003
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Table 4. Genotype distribution of the 12 polymorphisms in infants with or without RDS requiring MV and BPD.
RDS BPD
Gene Symbol db SNP Genotypes Non = 182 (%) Yesn = 160 (%) p Non = 271 (%) Yesn = 71 (%) p
ACE rs1799752 II 26 (14.3) 32 (20.0) 48 (17.7) 10 (14.1)
ID+DD 156 (85.7) 128 (80) 0.2 223 (82.3) 61 (85.9) 0.5
ACE Prom rs4291 AA 66 (36.3) 53 (33.1) 101 (37.3) 18 (25.4)
AT+TT 116 (63.7) 107 (66.9) 0.5 170 (62.7) 53 (74.6) 0.06
AGTR1 rs5186 AA 117 (64.3) 94 (58.8) 164 (60.5) 47 (66.2)
AC+CC 65 (35.7) 66 (41.3) 0.3 107 (39.5) 24 (33.8) 0.4
AGT rs699 MM 48 (26.4) 37 (23.1) 73 (26.9) 12 (16.9)
MT+TT 134 (73.6) 123 (77.9) 0.5 198 (73.1) 59 (83.1) 0.08
eNOS rs2070744 TT 71 (39.0) 60 (37.5) 113 (41.7) 18 (25.4)
TC+CC 111 (61.0) 100 (62.5) 0.8 158 (58.3) 53 (74.6) 0.01
rs1799983 GG 90 (49.5) 76 (47.5) 141 (52.0) 25 (35.2)
GT+TT 92 (50.5) 84 (52.5) 0.7 130 (48.0) 46 (64.8) 0.01
rs61722009 bb 133 (73.1) 114 (71.2) 197 (72.7) 50 (70.4)
ab+aa 49 (26.9) 46 (28.8) 0.7 74 (27.3) 21 (29.6) 0.7
VEGFA rs3025039 CC 126(69.2) 114(71.2) 184(67.9) 56(78.9)
CT+TT 56(30.8) 46(28.8) 0.6 87(32.1) 15(21.1) 0.07
VEGFA rs1547651 AA 143(78.6) 112(70.0) 202(74.5) 53(74.6)
GG+GA 39(21.4) 48(30.0) 0.06 69(25.5) 18(25.4) 0.9
VEGFA rs833058 CC 52(28.6) 57(35.6) 89(32.8) 20(28.2)
CT+TT 130(71.4) 103(64.4) 0.1 182(77.2) 51(72.8) 0.4
VEGFA rs833061 TT 54(29.7) 46(28.8) 76(28.0) 24(33.8)
CT+CC 128(70.3) 114(71.2) 0.8 195(72.0) 47(66.2) 0.3
HMOX1 rs3074372 LL 79 (43.4) 71 (44.4) 115 (42.4) 35 (49.3)
SL+SS 103 (56.6) 89 (55.6) 0.8 156 (57.6) 36 (50.7) 0.3
doi:10.1371/journal.pone.0131741.t004
Table 5. Univariate andmultivariate analysis for VEGF, ACT, AGT, eNOS polymorphisms.
RDS
Univariate Analysis Multivariate Analysis*
OR (95%CI) p OR (95%CI) p
rs 1547651 VEGFA T 1.57 (0.96–2.56) 0.07 1.47 (0.82–2.63) 0.2
BPD
Univariate Analysis Multivariate Analysis*
OR (95%CI) p OR (95%CI) p
rs 4291 ACE Prom -240T 1.75 (0.97–3.15) 0.06 1.61 (0.87–2.97) 0.13
rs699 AGT 235T 1.82 (0.93–3.58) 0.08 1.87 (0.92–3.84) 0.08
rs2070744 eNOS -786C 2.11 (1.17–3.79) 0.01 1.89 (1.03–3.46) 0.04
rs1799983 eNOS 894T 1.98 (1.15–3.41) 0.01 1.92 (1.09–3.39) 0.02
rs3025039 VEGF 936T 0.57 (0.30–1.06) 0.07 0.59 (0.31–1.12) 0.1
ROP
Univariate Analysis Multivariate Analysis*
OR (95%CI) p OR (95%CI) p
rs1799983 eNOS 894T 1.90 (1.00–3.71) 0.05 1.73 (0.83–3.64) 0.1
rs833061 VEGF -460C 0.66 (0.34–1.29) 0.2 0.74 (0.35–1.58) 0.4
rs833058 VEGFA T 1.63 (0.77–3.45) 0.2 1.28 (0.57–2.90) 0.5
doi:10.1371/journal.pone.0131741.t005
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Gestational age and birth weight were not associated with any of the analyzed polymor-
phisms (Table 7).
According to the multivariate analysis, adjusted for gestational age and birth weight, we
found that:
1) VEGFA haplotypes increase (ACCC, ACTC, ACTT, ATCC, TCCT) or decrease (ACCT,
TCCC) birth weight (Table 8); 2) the eNOS haplotype (TaG) decreases gestational age
(Table 8). We also found that the: 1) VEGFA haplotype (ACTT) decreases the risk of RDS and
increases the risk of BPD (Table 9); 2) the VEGFA haplotype (TCCT) decreases the risk of
ROP and increases the risk of IVH (Tble 9); 3) the rare (CaT and TaT) and CbT eNOS haplo-
types were significantly associated with different effects (risk for RDS and BPD and protection
from IVH and ROP) on clinical prematurity complications (Table 9).
Discussion
In this study we evaluated the possible association between VEGFA, eNOS, AGT, AGTR1, ACE,
andHMOX-1 gene polymorphisms and the development of the most frequent prematurity
complications, namely RDS requiring MV, BPD, IVH and ROP in a large population of preterm
infants. Our data demonstrate for the first time that the T allele of the rs1799983 eNOS poly-
morphism and confirm that C allele of the rs2070744 eNOS polymorphism are independent
Table 6. Genotype distribution of the 12 polymorphisms in infants with or without retinopathy of prematurity (ROP) and intraventricular hemor-
rhage (IVH).
ROP IVH
Gene Symbol db SNP Genotypes Non = 299 (%) Yesn = 43 (%) p Non = 272 (%) Yesn = 70 (%) p
ACE rs1799752 II 47 (15.7) 11 (25.6) 46 (16.9) 12 (17.1)
ID+DD 252 (84.3) 32 (74.4) 0.1 226 (83.1) 58 (82.9) 0.9
ACE Prom rs4291 AA 103 (34.4) 16 (37.2) 92 (33.8) 27 (38.6)
AT+TT 196 (65.6) 27 (62.8) 0.7 180 (66.2) 43 (61.4) 0.4
AGTR1 rs5186 AA 188 (62.9) 23 (53.5) 164 (60.3) 47 (67.1)
AC+CC 111 (37.1) 20 (46.5) 0.2 108 (39.7) 23 (32.1) 0.3
AGT rs699 MM 74 (24.7) 11 (25.6) 70 (25.7) 15 (21.4)
MT+TT 225 (75.3) 32 (74.4) 0.9 202 (74.3) 55 (78.6) 0.4
eNOS rs2070744 TT 116 (38.8) 15 (34.9) 105 (38.6) 26 (37.1)
TC+CC 183 (61.2) 28 (65.1) 0.6 167 (61.4) 44 (62.9) 0.8
rs1799983 GG 151 (50.5) 15 (34.9) 135 (49.6) 31 (44.3)
GT+TT 148 (49.5) 28 (65.1) 0.05 137 (50.4) 39 (55.7) 0.4
rs61722009 bb 214 (71.6) 33 (76.7) 197 (72.4) 50 (71.4)
ab+aa 85 (28.4) 10 (23.3) 0.5 75 (27.6) 20 (28.6) 0.9
VEGFA rs3025039 CC 210(70.2) 30(69.8) 193(71.0) 47(67.1)
CT+TT 89(29.8) 13(30.2) 79(29.0) 33(32.9) 0.5
0.9
VEGFA rs1547651 AA 221(73.9) 34(79.1) 203(74.6) 52(74.3)
GG+GA 78(26.1) 9(20.9) 0.5 69(25.4) 18(25.7) 0.9
VEGFA rs833058 CC 99(33.1) 10(23.3) 87(32.0) 22(31.4)
CT+TT 200(66.9) 33(76.7) 0.1 185(68.0) 48(68.6) 0.9
VEGFA rs833061 TT 84(28.1) 16(37.2) 76(27.9) 24(34.3)
CT+CC 215(72.9) 27(62.8) 0.2 196(72.1) 46(65.7) 0.3
HMOX1 rs3074372 LL 132 (44.1) 18 (41.9) 121 (44.5) 29 (41.4)
SL+SS 167 (55.9) 25 (58.1) 0.8 151 (55.5) 41 (58.6) 0.6
doi:10.1371/journal.pone.0131741.t006
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Table 7. Gestational age and birth weight at according to genotype distribution of studied polymorphisms.
Gestational Age at birth Weight at birth
Gene Symbol db SNP Genotypes n Median weeks (IQR Range) p n Median grams (IQR range) p
ACE rs1799752 II 58 26.7 (25.3–28.3) 58 900 (730–1120)
ID+DD 284 27.6 (25.8–28.5) 0.2 284 872 (725–1077) 0.5
ACE Prom rs4291 AA 119 27.6 (25.8–28.9) 119 910 (730–1120)
AT+TT 223 27.4 (25.7–28.4) 0.5 223 865 (730–1070) 0.3
AGTR1 rs5186 AA 211 27.4 (25.4–28.7) 211 870 (707.5–1082.5)
AC+CC 131 27.6 (26.0–28.4) 0.9 131 897.5 (747.5–1100) 0.4
AGT rs699 MM 85 27.2 (25.7–28.7) 85 910 (760–1125)
MT+TT 257 27.6 (25.5–28.4) 0.6 257 871 (711.2–1080) 0.3
eNOS rs2070744 TT 131 27.4 (26.3–28.5) 131 940 (754–1110)
TC+CC 211 27.6 (25.4–28.6) 0.6 211 865 (720–1075) 0.2
rs1799983 GG 166 27.7 (25.9–28.7) 166 900 (735–1120)
GT+TT 176 27.4 (25.4–28.4) 0.2 176 871 (720–1060) 0.2
rs61722009 Bb 247 27.6 (25.9–28.6) 247 890 (750–1100)
ab+aa 95 27.1 (25.3–28.3) 0.3 95 870 (700–1053.7) 0.3
VEGFA rs3025039 CC 240 27.6 (25.6–28.6) 240 867.5 (720–1097.5)
CT+TT 102 27.3 (25.8–28.4) 0.9 102 910 (760–1082.5) 0.4
VEGFA rs1547651 AA 255 27.6 (25.7–28.7) 255 880 (730–1100)
AT+TT 87 27.2 (25.6–28.3) 0.1 87 860 (720–1050) 0.4
VEGFA rs833058 CC 109 27.7 (26.1–28.6) 109 890 (755–1100)
CT+TT 233 27.4 (25.4–28.6) 0.5 233 880 (720–1080) 0.3
VEGFA rs833061 TT 100 27.2 (25.4–28.3) 100 872.5 (742.5–1047.5)
CT+CC 242 27.6 (26.0–28.6) 0.2 242 890 (720–1110) 0.6
HMOX1 rs3074372 LL 150 27.6 (25.7–28.6) 150 915 (745–1105)
SL+SS 192 27.6 (25.8–28.6) 0.9 192 865 (720–1085) 0.3
doi:10.1371/journal.pone.0131741.t007
Table 8. Haplotypes of VEGF and eNOS genes significantly associated with weight and gestational age at birth.
Gene Symbol Haplotype Frequency Coefficient Standard Error p-value
Weight at birth
VEGFA
ACCC 0.232 37.2 5.58 <0.0001
ACCT 0.065 -15.2 1.23 <0.0001
ACTC 0.103 22.2 2.08 <0.0001
ACTT 0.012 35.2 0.19 <0.0001
ATCC 0.022 40.6 0.39 <0.0001
TCCC 0.101 -47.9 1.91 <0.0001
TCCT 0.029 73.2 0.46 <0.0001
SNP1 = rs1547651, SNP2 = rs833058, SNP3 = rs833061, SNP4 = rs3025039
Gestational age at birth
VEGFA
ACCC 0.232 0.33 0.19 0.08
eNOS
TaG 0.021 -1.33 0.53 0.01
SNP1 = rs2070744, SNP2 = rs61722009, SNP3 = rs1799983
doi:10.1371/journal.pone.0131741.t008
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predictors of an increased risk of BPD in preterm infants. We also discovered that haplotypes of
VEGFA and eNOS genes may independently affect birth weight and gestational age.
Although further associations emerged from the univariate analysis, these correlations dis-
appeared after data adjustment for gestational age and birth weight, with the exception of TC
+CC rs2070744 eNOS and GT+TT rs1799983 eNOS genotypes which were independent risk
factors for BPD. We speculated that the lack of correlations of the different polymorphisms
“per se” was due to the multifactorial pathogenesis of studied prematurity complications which
were mainly governed by gestational age [26–30].
The role of the rs2070744 eNOS polymorphism in the pathogenesis of RDS and BPD has
been previously investigated in a cohort (n = 124) of preterm infants by Vannemreddy et al.
[6]. They found that the status of rs2070744 allele C carrier(TC+CC) was significantly more
frequent in infants with RDS, BPD, and IVH compared to control patients (15.3 vs. 7.3%,
p = 0.03) and represents a significant risk factor for the development of these pathologies [6]
Our data are in partial agreement with these findings because we did not observe any relation-
ship between the polymorphism and the risk of severe RDS and IVH, but we could confirm
that TC+CC rs2070744 eNOS genotypes are a risk factor for BPD. Previous reports have dem-
onstrated that TC heterozygotes and CC homozygotes for the rs2070744 eNOS polymorphism
increase the risk of cardiovascular diseases in adults and decreases NO levels [6,31]. Consider-
ing the crucial role of NO in promoting lung angiogenesis during the fetal/neonatal period
[2,32,33], we can reasonably speculate that the C allele of the polymorphism increases the risk
of BPD through the decrease of endothelial NO synthesis that impairs lung vessel growth and
in turn alveologenesis.
Similarly, the role of the rs1799983 eNOS polymorphism has been demonstrated in the
pathogenesis of cardiovascular diseases in adults [34,35], but has never been investigated in the
pathogenesis of prematurity complications. We found that GT+TT rs1799983 eNOS genotypes
increase the risk of BPD. It has been demonstrated that the T allele carrier status is associated
with reduced function of the enzyme and decreased NO production by endothelial cells com-
pared to GG homozygous subjects [36,37]. Therefore, these polymorphisms might also favor
BPD development through a negative effect on lung vessels and alveolar growth.
These considerations seem to be confirmed by the results of Ballard’s large randomized con-
trolled study demonstrating that prolonged inhaled NO treatment increases survival without
BPD in high- risk preterm infants, although its routine use can not be recommended [38].
Table 9. Haplotypes of the VEGF and eNOS genes significantly associated with the adverse outcomes.
Gene
Symbol
Outcome Haplotype Frequency in subjects without
adverse outcome
Frequency in subjects with
adverse outcome
Coefficient Standard
Error
p
VEGF
BPD ACTT 0.0009 0.038 0.8 0.01 <0.0001
RDS ACTT 0.013 0.008 -0.08 0.01 <0.0001
ROP TCCT 0.036 NA -0.1 0.07 0.03
IVH TCCT 0.019 0.064 0.3 0.1 0.02
SNP1 = rs1547651, SNP2 = rs833058, SNP3 = rs833061, SNP4 = rs3025039
eNOS
BPD CbT 0.197 0.294 0.09 0.04 0.02
SNP1 = rs2070744, SNP2 = rs61722009, SNP3 = rs1799983
NA: not applicable.
doi:10.1371/journal.pone.0131741.t009
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Interestingly, the multivariate analysis (adjusted for gestational age and birth weight) of the
polymorphism combinations by haplotype analysis of the polymorphisms localized in the same
gene showed that haplotypes of VEGFA increase or decrease birth weight and one haplotype of
eNOS decreases gestational age. Moreover, the VEGFA haplotype increases the risk of IVH and
BPD or decreases the risk of RDS and ROP, while the eNOS haplotype increases the risk of RDS
and BPD or decreases the risk of IVH and ROP. Although it is difficult to explain these different
effects, if we consider the crucial role of VEGFA [1,2] and NO [5,6] on fetal and neonatal vessel
growth and protection, we may speculate that protective haplotypes might enhance their benefi-
cial effects, and promote adequate tissue vascularization and perfusion, while unfavorable com-
binations might attenuate them and induce inadequate vessel development and blood flow.
Haplotype analysis allow us to identify alleles in which polymorphisms per se associated
with the diseases are included, and helps to better identify subjects who are either at risk or not
(e.g. VEGFA haplotypes for RDS, BPD, ROP, and IVH). Thus, our findings suggest that differ-
ent SNPs in VEGFA and eNOS genes of low frequency might change the patients’ susceptibility
to prematurity complications by altering either their function or their expression.
The limitations of our study include the relatively small size of the study which could affect
the demonstration of correlation between studied complications and polymorphisms; the lack
of measurement of infants’ VEGFA levels and NOS activity which precludes the possibility of
relating specific polymorphisms and haplotype combinations with their expression in our
patients. Thus, our findings do not allow us to demonstrate definitively whether the aforemen-
tioned SNPs and haplotypes are themselves responsible for their beneficial or detrimental
effects in our population or whether they reflect linkage disequilibrium with variation in the
remainder of the genes or perhaps in a nearby flanking gene. However, given the homogeneity
of our population, it is unlikely that the observed associations are a statistical artefact resulting
from a population substructure.
Conclusions
We confirm that the C allele of rs2070744 eNOS polymorphism is an independent predictor of
an increased risk of BPD in preterm infants and demonstrate for the first time the same thing
for the T allele of the rs1799983 eNOS polymorphism. We also find that haplotypes of VEGFA
and eNO genes may independently affect birth weight and gestational age, and act as protecting
or risk markers for prematurity complications. These results could be useful in identifying
patients at high risk of developing prematurity complications in whom prevention strategies
would be particularly indicated.
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